 randomized trial inoperable non-small-cell lung cancer vindesine cisplatin versus mitomycin vindesine cisplatin versus etoposide cisplatin vindesine mitomycin Patients inoperable non-small-cell lung cancer NSCLC dosage regimens vindesine cisplatin VP mitomycin vindesine cisplatin MVP etoposide cisplatin vindesine mitomycin EP/VM assessable patients response rates VP MVP EP/VM addition mitomycin VP regimen response rate response rate EP/VM regimen MVP regimen median survival times VP weeks MVP weeks EP/VM weeks differences significant III IV thrombocytopenia MVP patients VP Other toxicities similar groups Analyses prognostic factors treatment MVP sex histologic classification squamous cell carcinoma predictive improved response Important factors improved survival Cox regression analysis stage disease performance status sex weight loss diagnosis hemoglobin concentration